Development ofin vitromodels to demonstrate the ability of PecSys®, anin situnasal gelling technology, to reduce nasal run-off and drip
Open Access
- 26 April 2012
- journal article
- Published by Informa UK Limited in Drug Development and Industrial Pharmacy
- Vol. 39 (5), 816-824
- https://doi.org/10.3109/03639045.2012.707210
Abstract
Many of the increasing number of intranasal products available for either local or systemic action can be considered sub-optimal, most notably where nasal drip or run-off give rise to discomfort/tolerability issues or reduced/variable efficacy. PecSys, an in situ gelling technology, contains low methoxy (LM) pectin which gels due to interaction with calcium ions present in nasal fluid. PecSys is designed to spray readily, only forming a gel on contact with the mucosal surface. The present study employed two in vitro models to confirm that gelling translates into a reduced potential for drip/run-off: (i) Using an inclined TLC plate treated with a simulated nasal electrolyte solution (SNES), mean drip length [±SD, n = 10] was consistently much shorter for PecSys (1.5 ± 0.4 cm) than non-gelling control (5.8 ± 1.6 cm); (ii) When PecSys was sprayed into a human nasal cavity cast model coated with a substrate containing a physiologically relevant concentration of calcium, PecSys solution was retained at the site of initial deposition with minimal redistribution, and no evidence of run-off/drip anteriorly or down the throat. In contrast, non-gelling control was significantly more mobile and consistently redistributed with run-off towards the throat. In both models PecSys significantly reduced the potential for run-off/drip ensuring that more solution remained at the deposition site. In vivo, this enhancement of retention will provide optimum patient acceptability, modulate drug absorption and maximize the ability of drugs to be absorbed across the nasal mucosa and thus reduce variability in drug delivery.Keywords
This publication has 34 references indexed in Scilit:
- Increased brain radioactivity by intranasal 32P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gelsInternational Journal of Nanomedicine, 2012
- Formulation and Evaluation of In Situ Gelling Systems for Intranasal Administration of GastrodinAAPS PharmSciTech, 2011
- Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate in Breakthrough Cancer PainJournal of Pain and Symptom Management, 2011
- Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteersInternational journal of clinical pharmacology and therapeutics, 2010
- Development and Characterization of Mucoadhesive In Situ Nasal Gel of Midazolam Prepared with Ficus carica MucilageAAPS PharmSciTech, 2010
- Formulations of Fentanyl for the Management of PainDrugs, 2010
- Formulation and evaluation ofin situgels containing clotrimazole for oral candidiasisIndian Journal of Pharmaceutical Sciences, 2009
- Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: A randomized, multicenter, double-blind, single-dose, crossover studyClinical Therapeutics, 2008
- Thermoreversible-mucoadhesive Gel for nasal delivery of sumatriptanAAPS PharmSciTech, 2006
- Biological interactions between polysaccharides and divalent cations: The egg‐box modelFEBS Letters, 1973